Haemonetics Corporation

NYSE:HAE

Medical - Instruments & Supplies

Healthcare
$122.86 +1.15%

+$0.84 today

Market cap
$5.59B
Beta
0.54
P/E (TTM)
34.9
EPS (TTM)
$2.11
52W Low $47.32High $87.32

Volume 0.48M

Average 0.88M

HAE Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Haemonetics CorporationNYSE: HAE

Gross Margin · Q1 FY2027 · quarter ended Jun 2026

Gross margin holds steady near 59.8%

Gross margin was 59.8% in Q1 FY2027, up 0.1 pp from a year earlier. On a trailing-twelve-month basis it was 57.4%, up 0.6 pp year over year. Over 3 fiscal years it widened by 2.4 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
59.8%+2.5 pp QoQ
Last fiscal yearMar 2026
55.7%-1.5 pp YoY
LTMJun 2026
57.4%+0.6 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+0.1 pp——
1 year-1.5 pp——
3 years+2.4 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2026
55.7%
Year-over-year change
-1.5pp

Gross Margin vs competitors

How HAE compares with its peers on the latest reported figures

  • HAE's LTM Jun 2026 gross margin of 57.4% is the 5th highest of the 10 companies compared; the peer median is 54.7%.
  • Its year-over-year change of +0.6 pp is the 4th highest of 10, against a peer median of +0.0 pp.
  • Over three fiscal years its change of +2.4 pp compares with a peer median of -0.3 pp.
HAE Competitors Peer median
Gross Margin for HAE and competitors
Company Period LTM level YoY 3-year change
BEAMBeam Therapeutics Inc.LTM Jun 2026100.0% +0.0 pp+495.5 pp
CPRXCatalyst Pharmaceuticals, Inc.LTM Mar 202682.3% -3.8 pp+1.2 pp
LMATLeMaitre Vascular, Inc.LTM Mar 202672.4% +3.6 pp+6.6 pp
BHCBausch Health Companies Inc.LTM Jun 202671.8% +1.1 pp-0.3 pp
HAEHaemonetics CorporationLTM Jun 202657.4% +0.6 pp+2.4 pp
WRBYWarby Parker Inc.LTM Jun 202654.7% +0.2 pp-3.1 pp
XRAYDENTSPLY SIRONA Inc.LTM Mar 202648.9% -2.6 pp-4.2 pp
QDELQuidelOrtho CorporationLTM Mar 202645.0% -2.0 pp-12.6 pp
CONConcentra Group Holdings Parent, Inc.LTM Sep 202629.9% +1.5 pp+4.7 pp
ITGRInteger Holdings CorporationLTM Jul 202623.7% -1.3 pp-3.0 pp
Peer median (excluding HAE) 54.7%+0.0 pp-0.3 pp

Competitors are the stored peer set for HAE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Mar 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
FY2026
Mar 2026
Revenue993.2M1.17B1.31B1.36B1.33B
Cost of Revenue462.43M545.79M597.14M582.28M590.44M
Gross Profit530.77M622.87M711.92M778.55M743.59M
Gross Margin53.4%53.3%54.4%57.2%55.7%
Research & Development55.2M58.63M63.04M69.42M59.77M
Selling, General & Admin332.2M373.95M420.82M422.05M442.42M
Operating Expenses450.02M466.84M547.03M556.73M502.19M
Depreciation & Amortization97.75M93.31M97.22M115.59M111.72M
EBITDA202.92M260.51M304.05M362.69M268.45M
EBITDA Margin20.4%22.3%23.2%26.7%20.1%
Operating Income80.75M156.03M164.88M221.82M241.4M
Operating Margin8.1%13.4%12.6%16.3%18.1%
Interest Income00000
Interest Expense17.12M14.63M13.02M9.75M28.7M
Other Income / Expenses(17.12M)(14.63M)(13.02M)(9.75M)(113.37M)
Income Before Tax63.63M141.4M151.87M212.07M128.03M
Pre-Tax Margin6.4%12.1%11.6%15.6%9.6%
Income Tax Expense20.25M26M34.31M44.39M30.72M
Net Income43.38M115.4M117.56M167.68M97.31M
Net Margin4.4%9.9%9.0%12.3%7.3%
EPS (Basic)0.852.272.323.312.05
EPS (Diluted)0.842.242.293.312.05
Weighted Avg Shares51.05M50.78M50.71M50.33M47.18M
Weighted Avg Shares (Diluted)51.35M51.42M51.4M50.73M47.35M

Haemonetics Corporation

NYSE:HAE

Intrinsic Alpha fair value

Locked

Current Price

$122.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.